story of the week
Taselisib or Placebo With Fulvestrant in ER-Positive, PIK3CA-Mutant, HER2-Negative Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology